A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
A phase 3 trial of Trastuzumab rezetecan, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations is a phase 3 interventional study registered as NCT06430437 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin. Conditions listed: Non-Small Cell Lung Cancer With HER2- Mutations. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
- TrialSHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Shares Jiangsu Hengrui Pharmaceuticals, Cisplatin, Small-cell lung cancer, Non-small-cell lung cancer.